Relaxin-expressing adenovirus decreases collagen synthesis and up-regulates matrix metalloproteinase expression in keloid fibroblasts: In vitro experiments

Plastic and Reconstructive Surgery

Volumn 130, Issue 3, 2012, Pages

  Lee, Won Jai ^a,b   Choi, Il Kyu ^a,b   Lee, Ju Hee ^a,b   Lee, Jung Sun ^a,b   Kim, Yong Oock ^a,b   Rah, Dong Kyun ^a,b   Yun, Chae Ok ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; METALLOPROTEINASE; RELAXIN; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN;

ADENOVIRUS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL LINE; CYTOLOGY; DERMIS; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; KELOID; METABOLISM; PATHOLOGY; SECRETION (PROCESS); UPREGULATION; VIROLOGY;

ADENOVIRIDAE; CELL LINE; CELLS, CULTURED; COLLAGEN; DERMIS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; KELOID; METALLOPROTEASES; RELAXIN; SMAD3 PROTEIN; UP-REGULATION;

EID: 84866029784     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31825dbf56     Document Type: Article

References (40)

1. Burd A, Huang L. Hypertrophic response and keloid diathesis: Two very different forms of scar. Plast Reconstr Surg. 2005;116:150e-157e.
2. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998;4:19-24.
3. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: A review. Plast Reconstr Surg. 1999;104:1435-1458.
4. Tredget EE, Shankowsky HA, Pannu R, et al. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: Effects of interferon alpha-2b. Plast Reconstr Surg. 1998;102:1317-1328; discussion 1329-1330.
5. Luo S, Benathan M, Raffoul W, Panizzon RG, Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg. 2001;107:87-96.
6. Kikuchi K, Kadono T, Takehara K. Effects of various growth factors and histamine on cultured keloid fibroblasts. Dermatology 1995;190:4-8.
7. Myles ME, Russell JD, Trupin JS, Smith JC, Russell SB. Keloid fibroblasts are refractory to inhibition of DNA synthesis by phorbol esters: Altered response is accompanied by reduced sensitivity to prostaglandin E2 and altered downregulation of phorbol ester binding sites. J Biol Chem. 1992;267:9014-9020.
8. Uchida G, Yoshimura K, Kitano Y, Okazaki M, Harri K. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. Exp Dermatol. 2003; 12(Suppl 2):35-42.
9. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol. 2005;153:295-300.
10. Imaizumi R, Akasaka Y, Inomata N, et al. Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: Implications for mechanisms of keloid progression. Histopathology 2009;54:722-730.
11. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin: A pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther. 2006;112:38-56.
12. Samuel CS. Relaxin: Antifibrotic properties and effects in models of disease. Clin Med Res. 2005;3:241-249.
13. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: The hormone relaxin. Cell Mol Life Sci. 2007;64: 1539-1557.
14. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev. 2004;25:205-234.
15. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem. 1990;265:10681-10685.
16. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004;145:4125-4133.
17. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal disease. Kidney Int. 2006;69:1498-1502.
18. Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 2005;68:96-109.
19. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739-2745.
20. van der Westhuizen ET, Halls ML, Samuel CS, et al. Relaxin family peptide receptors: From orphans to therapeutic targets. Drug Discov Today 2008;13:640-651.
21. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst. 2006;98:1482-1493.
22. Flotte TR. Gene therapy: The first two decades and the current state-of-the-art. J Cell Physiol. 2007;213:301-305.
23. Ghali S, Dempsey MP, Jones DM, Grogan RH, Butler PE, Gurtner GC. Plastic surgical delivery systems for targeted gene therapy. Ann Plast Surg. 2008;60:323-332.
24. St George JA. Gene therapy progress and prospects: Adenoviral vectors. Gene Ther. 2003;10:1135-1141.
25. Stoff A, Rivera AA, Banerjee NS, et al. Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair Regen. 2006;14:608-617.
26. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 2002;9:725-736.
27. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805-4810.
28. Xu B, Liu ZZ, Zhu GY, et al. Efficacy of recombinant adenovirus-mediated double suicide gene therapy in human keloid fibroblasts. Clin Exp Dermatol. 2008;33:322-328.
29. Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001;59:876-882.
30. Bathgate RA, Lekgabe ED, McGuane JT, et al. Adenovirusmediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endocrinol. 2008;280:30-38.
31. Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009;23:1219-1229.
32. Wang Z, Gao Z, Shi Y, et al. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg. 2007;60:1193-1199.
33. Phan TT, Lim IJ, Aalami O, et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. J Pathol. 2005;207:232-242.
34. Phan TT, Lim IJ, Sun L, et al. Quercetin inhibits fibronectin production by keloid-derived fibroblasts: Implication for the treatment of excessive scars. J Dermatol Sci. 2003;33:192-194.
35. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
36. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
37. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg. 2000;105:638-647.
38. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;69:614-624.
39. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol. 2003;285:F59-F67.
40. Lee WJ, Kim YO, Choi IK, Rah DK, Yun CO. Adenovirusrelaxin gene therapy for keloids: Implication for reversing pathological fibrosis. Br J Dermatol. 2011;165:673-677.